The ParC and ParE subunits of E. coli Topo IV were expressed and purified, and the active enzyme was reconstituted as previously described [15 (link), 29 (link)]. The plasmid pBR322 DNA and kinetoplast DNA were purchased from New England Biolabs (Ipswich, MA, U.S.A.) and TopoGEN (Port Orange, FL, U.S.A.), respectively.
The 8-methyl-quinazoline-2,4-dione (UIJR1-048) and the 8-methoxy-quinazoline-2,4-dione (UING5-207) were synthesized as previously described [30 , 31 (link)]. Ciprofloxacin (CFX) and moxifloxacin were purchased from MP Biomedical Inc. (Irvine, CA, U.S.A.) and ChemPacific (Baltimore, MD, U.S.A.), respectively. Norfloxacin was purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.). Other chemicals and reagents were purchased from Sigma-Aldrich, Thermo Fisher Scientific (Waltham, MA, U.S.A.), or Roche Applied Science (Indianapolis, IN, U.S.A.).
The 8-methyl-quinazoline-2,4-dione (UIJR1-048) and the 8-methoxy-quinazoline-2,4-dione (UING5-207) were synthesized as previously described [30 , 31 (link)]. Ciprofloxacin (CFX) and moxifloxacin were purchased from MP Biomedical Inc. (Irvine, CA, U.S.A.) and ChemPacific (Baltimore, MD, U.S.A.), respectively. Norfloxacin was purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.). Other chemicals and reagents were purchased from Sigma-Aldrich, Thermo Fisher Scientific (Waltham, MA, U.S.A.), or Roche Applied Science (Indianapolis, IN, U.S.A.).